Literature DB >> 14689585

Galectins and urological cancer.

Natsuo Oka1, Yukinori Takenaka, Avraham Raz.   

Abstract

Galectins are a family of proteins defined by their affinity for beta-galactoside and by their conserved sequence. Each galectins exhibits a specific expression pattern in various tissues and their expression is regulated during development. Their expression is altered in many types of cancers and non-cancerous disorders. They interact with glycoproteins in both extracellular and intracellular milieu and regulate various biological phenomenon including cell growth, cell differentiation, cell adhesion, and apoptosis. A series of experimental and clinical evidences have been reported to support correlation between galectin expressions and neoplastic transformation. The recent findings show that expressions of galectins are elevated with neoplastic progression in certain malignancies, and therefore, galectins are expected to serve as reliable tumor markers. In this review, we describe the expression and role of galectins in urological cancers and their clinical applications for diagnostic and therapeutic use. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14689585     DOI: 10.1002/jcb.10663

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  9 in total

Review 1.  Significance of talin in cancer progression and metastasis.

Authors:  Andreas Desiniotis; Natasha Kyprianou
Journal:  Int Rev Cell Mol Biol       Date:  2011       Impact factor: 6.813

2.  [Galectin expression in urological cancer. Diagnostic, prognostic and therapeutic potential].

Authors:  S Waalkes; A S Merseburger; A Simon; J Serth; M A Kuczyk
Journal:  Urologe A       Date:  2010-03       Impact factor: 0.639

Review 3.  Anoikis and survival connections in the tumor microenvironment: is there a role in prostate cancer metastasis?

Authors:  Gabriela Rennebeck; Matthew Martelli; Natasha Kyprianou
Journal:  Cancer Res       Date:  2005-12-15       Impact factor: 12.701

4.  Galectin-3 expression is associated with bladder cancer progression and clinical outcome.

Authors:  Giacomo Canesin; Pilar Gonzalez-Peramato; Joan Palou; Manuel Urrutia; Carlos Cordón-Cardo; Marta Sánchez-Carbayo
Journal:  Tumour Biol       Date:  2010-04-17

5.  Immunoexpression of galectin-3 in colorectal cancer and its relationship with survival.

Authors:  Luciana Zaia Povegliano; Celina Tizuko Fujiyama Oshima; Flávio de Oliveira Lima; Pedro Luiz Andrade Scherholz; Nora Manoukian Forones
Journal:  J Gastrointest Cancer       Date:  2011-12

Review 6.  Glycosylation in bladder cancer.

Authors:  Chikara Ohyama
Journal:  Int J Clin Oncol       Date:  2008-08-15       Impact factor: 3.402

7.  Restoration of compact Golgi morphology in advanced prostate cancer enhances susceptibility to galectin-1-induced apoptosis by modifying mucin O-glycan synthesis.

Authors:  Armen Petrosyan; Melissa S Holzapfel; David E Muirhead; Pi-Wan Cheng
Journal:  Mol Cancer Res       Date:  2014-08-01       Impact factor: 5.852

8.  Promoter hypermethylation of LGALS4 correlates with poor prognosis in patients with urothelial carcinoma.

Authors:  Meei-Maan Wu; Ching-Fei Li; Li-Fang Lin; Alexander Sheng-Shin Wang; Yeong-Shiau Pu; Hsiu-Hua Wang; Ai-Chung Mar; Chien-Jen Chen; Te-Chang Lee
Journal:  Oncotarget       Date:  2017-04-04

9.  Expression of galectin-7 is induced in breast cancer cells by mutant p53.

Authors:  Carole G Campion; Marilyne Labrie; Geneviève Lavoie; Yves St-Pierre
Journal:  PLoS One       Date:  2013-08-14       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.